CAMBRIDGE, Mass. — An explosion of biological data will lead to the first drug candidates discovered by an artificial intelligence system within the next few years, a feat that promises to change the way pharmaceutical companies conduct research.
That was a consensus opinion that emerged among experts in machine learning who spoke at the STAT Summit Thursday about the use of AI in the pharmaceutical industry.
“I would predict that within the next two to three years we’ll have examples of [drug] targets … discovered through machine learning methods that unravel biology that wasn’t appreciated before,” said Dr. Hal Barron, chief scientific officer of GlaxoSmithKline.
About the Author Reprints
